Patents by Inventor Philip Avner

Philip Avner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of determining the susceptibility of a subject to developing insulin-dependent diabetes
    Patent number: 7960107
    Abstract: The present application identifies the involvement of the HIF?-homologous Arntl2 gene in the control of type 1 (insulin-dependent) diabetes. Accordingly, the present invention provides a method of determining the susceptibility of a subject to developing insulin-dependent diabetes based on the expressing level of the Arntl2 gene. The present invention also provides a method for identifying compounds effective for treating or preventing insulin-dependent diabetes in a subject in need thereof and a method of treating or preventing insulin-dependent diabetes by administering an effective amount of compound identified by the identification method. The present invention also provides a method of enhancing protection against insulitis progression or autoimmune diabetes development in a subject in need thereof comprising, enhancing expression of the Arntl2 gene or modulating the expression of target genes thereof.
    Type: Grant
    Filed: February 27, 2007
    Date of Patent: June 14, 2011
    Assignee: Institut Pasteur
    Inventors: Philip Avner, Ute Christine Rogner, Ming-Shiu Hung
  • TRANSCRIPTION FACTOR ARNTL2 GENE AND EXPRESSION PRODUCTS THEREOF USED IN THE DIAGNOSIS, PREVENTION, AND TREATMENT OF TYPE 1 DIABETES
    Publication number: 20090181915
    Abstract: The present application identifies the involvement of the HIF?-homologous Arntl2 gene in the control of type 1 (insulin-dependent) diabetes. Accordingly, the present invention provides a method of determining the susceptibility of a subject to developing insulin-dependent diabetes based on the expressing level of the Arntl2 gene. The present invention also provides a method for identifying compounds effective for treating or preventing insulin-dependent diabetes in a subject in need thereof and a method of treating or preventing insulin-dependent diabetes by administering an effective amount of compound identified by the identification method. The present invention also provides a method of enhancing protection against insulitis progression or autoimmune diabetes development in a subject in need thereof comprising, enhancing expression of the Arntl2 gene or modulating the expression of target genes thereof.
    Type: Application
    Filed: February 27, 2007
    Publication date: July 16, 2009
    Applicant: INSTITUT PASTEUR
    Inventors: Philip Avner, Ute Christine Rogner, Ming-Shiu Hung
  • TRANSCRIPTION FACTOR ARNTL2 GENE AND EXPRESSION PRODUCTS THEREOF USED IN THE DIAGNOSIS, PREVENTION, AND TREATMENT OF TYPE 1 DIABETES
    Publication number: 20070214510
    Abstract: The present application identifies the involvement of the HIF?-homologous Arntl2 gene in the control of type 1 (insulin-dependent) diabetes. Accordingly, the present invention provides a method of determining the susceptibility of a subject to developing insulin-dependent diabetes based on the expressing level of the Arntl2 gene. The present invention also provides a method for identifying compounds effective for treating or preventing insulin-dependent diabetes in a subject in need thereof and a method of treating or preventing insulin-dependent diabetes by administering an effective amount of compound identified by the identification method. The present invention also provides a method of enhancing protection against insulitis progression or autoimmune diabetes development in a subject in need thereof comprising, enhancing expression of the Arntl2 gene or modulating the expression of target genes thereof.
    Type: Application
    Filed: February 27, 2007
    Publication date: September 13, 2007
    Applicant: INSTITUT PASTEUR
    Inventors: Philip Avner, Ute Rogner, Ming-Shiu Hung
  • Idetification of neural defects associated with the nucleosomal assembly protien 1l 2 gene
    Publication number: 20040029822
    Abstract: A method for screening neural system defects in a human comprises: (A) providing chromosomal material from the human; (B) detecting a modification of the NAP1L2 gene in the chromosomal material, wherein the modification is selected from a) substitution, b) deletion, c) frame-shift, or d) insertion that causes a loss of biological function in the NAP1L2 gene; and (C) correlating the modification of the gene with a potential for a neural system defect. The method can also be practiced with the mouse Nap1l2 gene.
    Type: Application
    Filed: July 15, 2003
    Publication date: February 12, 2004
    Inventors: Philip Avner, Christine Rogner Ute, Demetri Spyropoulos, Claire Rougeulle